Discover
NMRA
Neumora Therapeutics, Inc. Common Stock
1.61
2 x 1.57
4 x 1.67
bid
ask
-
0.01
0.92%
1 @ 04:00 PM
1.65 +0.03 (2.17%)
| Ytd | -9.78% | |
| 1y | -17.60% |
1.59
day range
1.67
0.83
52 week range
3.65
| Open | 1.64 | Prev Close | 1.63 | Low | 1.59 | High | 1.67 | Mkt Cap | 299.23M |
| Vol | 402.75K | Avg Vol | 2.20M | EPS | -1.33 | P/E | -1.21 | Forward P/E | -1.01 |
| Beta | 2.74 | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.68 | 200-d Avg | 2.19 | 1yr Est | 11.77 |
| Income Statement | |||
| Operating Expenses | 52.86M | ||
| Research and Development Expense | 38.60M | ||
| Selling, General and Administrative Expense | 14.27M | ||
| Operating Income | -52.86M | ||
| Interest Expense | 1.85M | ||
| Income Tax Expense | 30.00K | ||
| Net Income | -53.46M | ||
| Net Income Common Stock | -53.46M | ||
| Net Income Common Stock (USD) | -53.46M | ||
| Consolidated Income | -53.46M | ||
| Earnings per Basic Share | -0.30 | ||
| Earnings per Basic Share (USD) | -0.30 | ||
| Earnings per Diluted Share | -0.30 | ||
| Earning Before Interest & Taxes (EBIT) | -51.57M | ||
| Earning Before Interest & Taxes (USD) | -51.57M | ||
| Weighted Average Shares | 179.87M | ||
| Weighted Average Shares Diluted | 179.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 147.07M | ||
| Cash and Equivalents (USD) | 147.07M | ||
| Current Assets | 153.43M | ||
| Property, Plant & Equipment Net | 390.00K | ||
| Total Assets | 153.88M | ||
| Debt Current | 291.00K | ||
| Total Debt | 53.37M | ||
| Current Liabilities | 30.12M | ||
| Debt Non-Current | 53.08M | ||
| Total Liabilities | 83.20M | ||
| Accumulated Retained Earnings (Deficit) | -1.24B | ||
| Shareholders Equity | 70.68M | ||
| Shareholders Equity (USD) | 70.68M | ||
| Assets Non-Current | 443.00K | ||
| Total Debt (USD) | 53.37M | ||
| Liabilities Non-Current | 53.08M | ||
| Trade and Non-Trade Payables | 5.06M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 67.00K | ||
| Net Cash Flow from Financing | 10.88M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -35.46M | ||
| Capital Expenditure | 71.00K | ||
| Issuance (Purchase) of Equity Shares | 10.88M | ||
| Net Cash Flow from Investing | 71.00K | ||
| Net Cash Flow from Operations | -46.40M | ||
| Share Based Compensation | 7.41M | ||